The Phase II study is expected to read out in mid-2025
A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis, The New England Journal of Medicine (2021) Nonalcoholic steatohepatitis (NASH), Cedars-Sinai Treatment of Alzheimers disease: Beyond symptomatic therapies, International Journal of Molecular Sciences (2023) Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs, Journal of Clinical Medicine (2023) The impact of insulin resistance on loss of lung function and response to treatment in asthma, American Journal of Respiratory and Critical Care Medicine (2022) The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials, Diabetology & Metabolic Syndrome (2023) Highlights of prescribing information, Food and Drug Administration (2023) Drug label information, DailyMed (2023) Medications containing semaglutide marketed for Type 2 diabetes or weight loss, Food and Drug Administration (2024) Diabetic nephropathy (kidney disease), Johns Hopkins Medicine Safety of semaglutide, Frontiers in Endocrinology (2021) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
This step includes checking for possible allergies, other medicines, and medical conditions that may interact with semaglutide
As I mentioned, my perfect meal plan includes pizza
